{"container_type": "Publication", "source": "AUTHOR_PUBLICATION_ENTRY", "bib": {"title": "Cost-Utility Analysis of Alemtuzumab Versus Subcutaneous Interferon Beta-1A for the Treatment of Relapsing-Remitting Multiple Sclerosis: US Payer Perspective", "pub_year": 2017, "citation": "VALUE IN HEALTH 20 (5), A193-A193, 2017", "author": "A Smith and L Hashemi and T Wandstrat", "conference": "VALUE IN HEALTH", "volume": "20", "number": "5", "pages": "A193-A193", "publisher": "ELSEVIER SCIENCE INC"}, "filled": true, "author_pub_id": "mSp4V_4AAAAJ:EcS_2O1c4Q0C", "num_citations": 0, "pub_url": "https://scholar.google.com/scholar?cluster=12474846174730731734&hl=en&oi=scholarr", "cites_per_year": {}}